Medically Tailored Meals Are Saving Costs in 49 States
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, April 11, 2025 -- Medically tailored meals (MTMs) are net cost-saving in the first year in 49 states, assuming full uptake among eligible patients with diet-related diseases and limitations in activities of daily living, according to a study published in the April issue of Health Affairs.
Using a population-based, open-cohort simulation model, Shuyue Deng, from Tufts University in Boston, and colleagues estimated state-specific one-year and five-year changes in annual hospitalizations, health care spending, and cost-effectiveness of MTMs for patients with diet-related diseases and limitations in activities of daily living who were covered by Medicaid, Medicare, or private insurance.
The researchers found that MTMs were net cost-saving in the first year in 49 states assuming full uptake among eligible people, with the largest savings seen in Connecticut ($6,299 per patient). Alabama was the exception, where MTMs were cost-neutral. To avert one hospitalization, the number of treated patients varied from 2.3 in Maryland to 6.9 in Colorado.
"The most striking finding is that medically tailored meals, assuming full uptake by eligible individuals, were cost-saving in 49 of 50 states, highlighting their potential to reduce both financial and health burdens," Deng said in a statement. "These results emphasize the potential for policymakers to integrate medically tailored meals into health care coverage at scale."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-04-12 12:00
Read more

- Eye Exam Can Assess Risk Of Delirium Following Surgery
- Some Folks Hit With Fees for Using Health Care Message Portals
- Low Creatinine-to-Cystatin C Ratio Tied to Lower Muscle Volume in Midlife Women
- 'Weekend Warriors' Reap Similar Health Benefits As Steady Exercisers
- Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on Disability Progression in Multiple Sclerosis
- Metal Mixtures During Pregnancy May Lower Midlife Hypertension Risk
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions